Liver transplantation: The current situation

Seminars in Liver Disease

Volumn 29, Issue 1, 2009, Pages 3-18

  Adam, Rene ^a,b,c,d,e   Hoti, Emir ^a,b,c,d  

^a Centre Hepatobiliaire   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Immunosuppression; Living related liver transplant; Split liver transplant; Transplant indications

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ALCOHOL LIVER DISEASE; ARTICLE; BILE DUCT CARCINOMA; COLD ISCHEMIA; DIABETES MELLITUS; DONOR SELECTION; DRUG SCREENING; DYSLIPIDEMIA; GRAFT REJECTION; GRAFT SURVIVAL; GROUPS BY AGE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NEUROTOXICITY; OBESITY; ORGAN DONOR; OSTEOPOROSIS; OUTCOME ASSESSMENT; PNEUMONIA; PORTAL VEIN THROMBOSIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RETRANSPLANTATION; STEATOSIS; SURGICAL TECHNIQUE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; LIVER DISEASES; LIVER TRANSPLANTATION; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; TREATMENT OUTCOME;

EID: 63049094222     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0029-1192052     Document Type: Article

References (108)

1. European Liver Transplant Registry. Data analysis booklet. Paris 2007. Available at: http://www.eltr.org. Accessed August 2008
2. United Network for Organ Sharing. Available at; www.unos.org/data/about/ viewDataReports. Accessed August 2008
3. Everhart JE, Beresford TP. Liver transplantation for alcoholic liver disease: a survey of transplantation programs in the United States. Liver Transpl Surg 1997; 3:220-226
4. Perney P, Bismuth M, Siguard H, et al. Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease? Transpl Int 2005; 18:1292-1297
5. Miguet M, Monnet E, Vanlemmens C, et al. Predictive factors of alcohol relapse after orthotopic liver transplantation for alcoholic liver disease. Gastroenterol Clin Biol 2004; 28:845-851
6. Tome S, Martinez-Rey C, Gonzales-Quintela A, et al. Influence of superimposed alcoholic hepatitis on the outcome of liver transplantation for end-stage liver disease, J Hepatol 2002; 36:793-798
7. Neuberger J, Schuiz KH, Day C, et al. Transplantation for alcoholic liver disease, j Hepatol 2002; 36:130-137
8. Pageaux GP, Bismuth M, Penny P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol 2003; 38:629-634
9. Johnson MW, Washburn WK, Freeman RB, et al. Hepatitis C viral infection in liver transplantation. Arch Surg 1996; 131:284-291
10. 10.Rosen HR, O'Reilly PM, Shacldeton CR, et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1996; 62:1773-1776
11. Russo MW, Galanko j, Beavers K, et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10:340-346
12. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699
13. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma; expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33: 1394-1403
14. Edwards E, Harper A. Does MELD work for relisted candidates? Liver Transpl 2004; 10:S10-S16
15. Castells L, Escartin A, Bilbao I, et al Liver transplant in HIV-HCV coinfected patients: a case control study. Transplantation 2007;83:354-358
16. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006; 26:273-284
17. Sudan D, De Roover A, Chinnakotla S, et al. Radio-chemotherapy and transplantation allows long term survival for non resectable hilar cholangiocarcinoma. Am J Transplant 2002; 2: 774-779
18. Shaw BW, Iwatsuki S, Bron K, Starzl TE. Portal vein grafts in hepatic transplantation. Surg Gynecol Obstet 1985; 161:66-68
19. O'GradyJG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445
20. Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hematology 1986;6:648-651
21. Grazi GL, Cescon M, Ravaioli M, et al. A revised consideration on the use of very aged donors for liver transplantation. Am J Transplant 2001;1:61-68
22. Verran D, Kusyk T, Painter D, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9:500-505
23. Russo MW, Galanko JA, Zacks SL, et al. Impact of donor age and year of transplantation on graft survival in liver transplant recipients with chronic hepatitis C. Am J Transplant 2004;4:1133-1138
24. Rayhill SC, Wu YM, Katz DA, et al. Older donor livers show early histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007; 84:331-339
25. Strasberg SM, Howard TK, Molmenti EP, et al. Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology 1994; 20:829-838
26. Pedotti P, Cardillo M, Rigotti P, et al. A comparative prospective study of two available solutions for kidney and liver transplantation. Transplantation 2004;77:1540-1545
27. 27.Adam R, Caillez V, Majno P, et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet 2000;356:621-627
28. Briceno J, Marchal T, Padillo J, et al. Influence of marginal donors on liver preservation injur)'. Transplantation 2002; 74:522-526
29. Pirawisuth T, Tredger JM, Hayllar KA, Williams R. Contribution of true cold and rewarming ischemia times to factors determining outcome after orthotopic liver transplantation. Liver Transpl Surg 1995;1:296-301
30. Clavien PA, Harvey PR, Strasberg SM. Preservation and reperfusion injuries in liver grafts. An overview and synthesis of current studies. Transplantation 1992;53:957-978
31. Dunne JB, Piratvisuth T, Williams R, Tredger JM. Treatment of experimental ischemia/reperfusion injury with S-adenyosylmethionine: evidence that donor pretreatment complements other regimens. Transplantation 1997; 63:500-506
32. Nery JR, Nery-Avila C, Reddy KR, et al. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75:1179-1186
33. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132:931-937
34. Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C donors. Transplantation 2002; 73:582-587
35. Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-negative patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 2001;7:762-768
36. Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV allografts. Liver Transpl 2006;12:1496-1503
37. Pomfret EA, PomposelliJJ, Lewis WD, et al. Live donor adult liver transplantation using right lobe grafts: donor evaluation and surgical outcome. Arch Surg 2001; 136:425-433
38. Grewal HP, Shokouh-Amiri MH, Vera S, Stratta R, Bagous W, Gaber AO. Surgical technique for right lobe adult living donor living transplantation without venovenous by pass or portocaval shunting and with duct-to-duct biliary reconstruction. Ann Surg 2001;233:502-508
39. Trotter JF, Adam R, Lo CM, Kenison J. Documented deaths of hepatic lobe donors for living donor liver transplantation. Liver Transpl 2006; 12:1485-1488
40. Renz JF, Roberts JP. Long-term complications of living donor liver transplantation. Liver Transpl 2000; 6:S73-S76
41. Liver Donation. New York State Committee on Quality Improvement in Living Liver Donation. Available at: http;//www.health.state.ny,us/nysdoh/liver- donation. Accessed August 2008
42. Berg CL, Gillespie BW, Merion RM, et al; A2ALL Study Group. Improvement in survival associated with adult- to-adult living donor transplantation, Gastroenterology 2007; 133:1806-1813
43. Humar A, Ramcharan T, Sielaff TD, et al. Split liver transplantation for two adult recipients: an initial experience. Am J Transplant 2001;1:366-372
44. Andorno E, Genzone A, Morelli N, et al. One liver for two adults; in situ split liver transplantation for two adult recipients. Transplant Proc 2001; 33:1420-1422
45. Azoulay D, Castaing D, Adam R, et al. Split-liver transplantation for two adult recipients: feasibility and long-term outcomes, Ann Surg 2001;233:565-574
46. Giacomoni A, Lauterio A, Donadon M, et al, Should we still offer split-liver transplantation for two adult recipients? A retrospective study of our experience Liver Transpl 2008; 14:999-1006
47. Berg CL, Gillespie BW, Merion RM, et al. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 2007; 133:1806-1813
48. Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A, Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation 2003; 75:1659-1663
49. Foley DP, Fernandez LA, Laverson G, et al. Donation after cardiac death: the University of Wisconsin experience with liver transplantation. Ann Surg 2005; 242:724-731
50. Axelrod DA, Schnitzler M, Salavalaggio PR, Swindle J, Abecassis MM. The economic impact of the utilization of liver allografts with high donor risk index. Am J Transplant 2007; 7:990-997
51. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure; The concept of a donor risk index. Am J Transplant 2006; 6:783-790
52. Schaubel DE, Sima CS, Goodrich NP, et al. Survival benefit of transplantation by MELD and donor risk index. Am J Transplant 2006; 6:95
53. Cameron AM, Ghobrial RM, Yersiz H, et al, Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006; 243:748-753
54. Muiesan P, Girlanda R, Jassem W, et al. Single-center experience with liver transplantation from controlled non-heartbeating donors: a variable source of grafts. Ann Surg 2005;242:732-738
55. Fujita S, Misuno S, Fujikawa T, et al. Liver transplantation from donation after cardiac death; a single center experience. Transplantation 2007; 84:46-49
56. Abt PL, Desai NM, Crawford MD, et al. Survival following transplantation from non-heart-beating donors. Ann Surg 2004; 239:87-92
57. Merion KM, Pelletier SJ, Goodrich N, et al. Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg 2006; 244:555-562
58. Roberts JP, Hulbert-Shearon TE, Merion RM, Wolfe RA, Port FK, Influence of graft type on outcomes after pediatric liver transplantation. Am J Transplant 2004; 4:373-377
59. Sindhi R, Rosendale R, Mundy D, et al. Impact of segmental grafts on pediatric liver transplantation-a review of the United Network for Organ Sharing Scientific Registry data (1990-1996). J Pediatr Surg 1999; 34:107-111
60. Otte JB, de Ville de Goyet J, Reding R, et al. Living related donor liver transplantation in children: the Brussels experience. Transplant Proc 1996; 28:2378-2379
61. Boillot O, Belghiti J, Azoulay D, Gugenheim J, Soubrane O, Cherqui D, Initial French experience in adult-to-adult living donor liver transplantation. Transplant Proc 2003; 35:962-963
62. Foster R, Zimmerman M, Trotter JF. Expanding donor options: marginal, living and split liver donors, Clin Liver Dis 2007;11:417-429
63. Olthoff KM, Merion RM, Ghobrial RM, et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2A11 Consortium. Ann Surg 2005; 242:314-323
64. Patel S, Orloff KM, Tsoulfas G, et al. Living donor liver transplantation in the United States: identifying donors at risk for perioperative complications. Am J Transplant 2007; 7:2344-2349
65. Garcia Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699-707
66. Shiffman ML, Stravitz RT, Contos ML, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor compared to cadaveric liver transplantation, Liver Transpl 2004; 10:1248-1255
67. Terrault NA, Shiffman ML, Lok AS, et al. Outcomes of hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13:122-129
68. Schmeding M, Neumann UP, Puhl G, Bahra M, Neuhaus R, Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl 2007; 13:687-692
69. Sarasin FP, Majno PE, Llovet JM, et al. Living donor liver transplantation for early hepatocarcinoma: a life expectancy and cost effectiveness perspective. Hepatology 2001; 33:1073-1079
70. Todo S, Furukawa H, Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004; 240:451-459
71. D'Alessandro AM, Knechtle SJ, Chin LT, et al. Liver transplantation in pediatric patients: twenty years of experience at the University of Wisconsin. Pediatr Transplant 2007; 11:661-670
72. Washburn K, Halff G, Mieles L, et al. Split-liver transplantation: results of statewide usage of the right trisegmental graft. Am J Transplant 2005;5:1652-1659
73. Yersiz H, Renz JF, Farmer DG, et al. One hundred in situ split-liver transplantations: a single-center experience. Ann Surg 2003; 238:496-505
74. Wilms C, Walter J, Kaptein M, et al. Long-term outcome of split liver transplantation using right extended grafts in adulthood: a matched paired analysis. Ann Surg 2006; 244:865-872
75. Cardillo M, De Fazio N, Pedotti P, et al. Split and whole liver transplantation outcomes: a comparative cohort study. Liver Transpl 2006; 12:402-410
76. Helderman JH, Bennet WM, Cibrik DM, et al. Immunosuppression practice and trends. Am J Transplant 2003; 3:41-52
77. Eason JD, Nair S, Cohen AJ, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003 ;75: 1396-1399
78. Heffron TG, Smallwood GA, Pillen T, et al. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant Proc 2002; 34:1514-1515
79. Pageaux GP, Calmus Y, Boillot O, et al; French CHI-F-01 Study Group. Steroid withdrawal at day 14 after liver transplantation: a double-blind, placebo-controlled study. Liver Transpl 2004; 10:1454-1460
80. Ringe B, Braun F, Schutz E, et al. A novel management strategy of steroid free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71:508-515
81. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev 2006; 4:CD005161
82. McAlister VC, Haddad EM, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a metaanalysis. Am J Transplant 2006; 6:1578-1585
83. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7:442-450'
84. Zaghla H, Selby RR, Chan LS, et al. A comparison of sirolimus vs. calcineurin inhibitor-based immunosuppressive therapies in liver transplantation. Aliment Pharmacol Ther 2006; 23:513-520
85. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006; 12:1640-1648
86. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003;35:193S-200S
87. Karam VH, Gasquet I, Delvart V, et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 2003; 76:1699-1704
88. Tome S, Wells JT, Said A, Lucey MR. Quality of life after liver transplantation. A systematic review. J Hepatol 2008; 48:567-577
89. Johnston SD, Morris JK, Cramb R, et al. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73:901-906
90. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of nonrenal organ. N Engl J Med 2003; 349:931-940
91. Vallejo GH, Romero CJ, Vincente JC. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hematol 2005; 56:87-99
92. Herrero JI, Lorenzo M, Quiroga J, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005; 11:89-97
93. Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007; 83:231-233
94. Fukumoto T, Berg T, Ku Y, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation; evidence for rapid turnover of serum virions. Hepatology 1996; 103:1351-1354
95. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of sustained virological response after liver transplantation, Liver Transpl 2006; 12:51-57
96. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporine A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288
97. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006; 12:1813-1824
98. Duclos Vallee JC, Sebagh M, Rifai K, et al. A 10 year follow-up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biological recurrence. Gut 2003; 52:893-897
99. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center.Hepatology 2001; 33:22-27
100. Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002; 8:575-581
101. Goto T, Yamashita T, T Ueda M, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant 2006; 6:2512-2515
102. Stangou AJ, Heaton N, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005; 352:2356-2359
103. Farese S, Trost N, Candinas D, Huynh-Do U. Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria. Nephrol Dial Transplant 2005; 20:2557-2560
104. Franchello A, Paraluppi G, Romanogli R, et al. Severe course of primary hyperoxaluria and renal failure after domino hepatic transplantation. Am J Transplant 2005; 5:2324-2327
105. Sousa MM, Ferrao J, Fernandes R, et al. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest 2004; 84:865-873
106. Takei Y, Gono T, Yazaki M, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl 2007; 13:215-218
107. Chen 'Z, Yan L, Li B, et al. Successful adult-to-aduit living donor liver transplantation combined with cadaveric split left lateral segment. Liver Transpl 2006; 12:1557-1559
108. Heaton N, Srinivasan P, Prachalias A, Rela M. Overcoming the limitation of living donor and split liver transplantation: a proposal for adult recipients (the best of the East in the West). Liver Transpl 2008; 14:932-934